GFRAL (JMT-203 Biosimilar Antibody)重組單克隆抗體是一種針對(duì)GFRAL（GDNF家族受體α樣蛋白）靶點(diǎn)研發(fā)的生物制劑，主要應(yīng)用于科研領(lǐng)域。該抗體通過基因工程技術(shù)重組表達(dá)，具有高特異性和親和力，能夠精準(zhǔn)識(shí)別并結(jié)合GFRAL蛋白，為相關(guān)生物學(xué)機(jī)制研究提供重要工具。 在科研應(yīng)用中，GFRAL (JMT-203 Biosimilar Antibody)重組單克隆抗體可用于多種實(shí)驗(yàn)場(chǎng)景，包括，助力研究者深入探究GFRAL在能量代謝、體重調(diào)節(jié)、神經(jīng)退行性疾病等生理病理過程中的作用機(jī)制。其高度純化的特性確保了實(shí)驗(yàn)結(jié)果的穩(wěn)定性和可重復(fù)性，適用于細(xì)胞水平和動(dòng)物模型的相關(guān)研究。 該抗體的研發(fā)基于對(duì)GFRAL信號(hào)通路的深入理解，為探索GFRAL作為潛在治療靶點(diǎn)的科學(xué)價(jià)值提供了關(guān)鍵支持。通過特異性阻斷或激活GFRAL受體，研究者可系統(tǒng)性分析其下游信號(hào)傳導(dǎo)途徑，為代謝性疾病、神經(jīng)系統(tǒng)疾病等領(lǐng)域的基礎(chǔ)研究和藥物靶點(diǎn)發(fā)現(xiàn)奠定基礎(chǔ)。目前，GFRAL (JMT-203 Biosimilar Antibody)重組單克隆抗體已成為相關(guān)科研領(lǐng)域的重要實(shí)驗(yàn)試劑，推動(dòng)著對(duì)GFRAL生物學(xué)功能的深入探索。

Q6UXV0

JMT203 research-grade biosimilar; JMT 203 research-grade biosimilar; JMT-203 research-grade biosimilar ;GFRAL antibody; C6orf144 antibody; UNQ9356/PRO34128 antibody; GDNF family receptor alpha-like antibody

Human

Recombinant Human GFRAL protein

Homo sapiens (Human)

Non-conjugated

Monoclonal

It differs from different batches. Please contact us to confirm it.

0.01M PBS，pH7.4

Liquid

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

3-4 weeks

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.